Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

59459 1490631916HCLSReviewIrelandMarch2017.pdf
Energy Boardroom

FDA-nixed diabetes drug from Lilly, Boehringer could face rough path to stardom

23.05.2014 / Fierce Pharma

The FDA may not have been so keen on Boehringer Ingelheim and Eli Lilly's Type 2 diabetes drug Jardiance when it issued a complete response letter in March for problems at its future production site. That didn't stop its across-the-pond counterpart from green-lighting the drug Friday–and it won't keep it from cracking the blockbuster barrier, analysts say. But that doesn't mean getting there will be easy.

Cover_HCLS_Ireland LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: